This article was originally published in Pharmaceutical Approvals Monthly
Interferon beta-1a treatment reduced the rate at which high-risk individuals develop clinically definite multiple sclerosis by 44% compared to placebo, according to a study published in the Sept. 28 New England Journal of Medicine. The 383-patient study also showed that 20 mcg Avonex injected intramuscularly once a week for up to three years had "a highly significant positive impact in reducing the rate at which patients developed brain abnormalities, or lesions, visible on MRI scans" compared to placebo, according to the company. Biogen plans to apply for an expanded label to reflect this early treatment regime
You may also be interested in...
COVID-19 has disrupted the operational schedules of health care and technology providers alike to unparalleled levels in 2020. But scratch the surface, and outcomes-oriented, value-based health care targets remains a priority – albeit competing a little harder for attention at present.
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
Kim Trautman, who authored the US FDA’s Quality System Regulation in the 1990s, tells Medtech Insight that the agency probably won’t release a draft of its updated, harmonized QSR until next year thanks in part to a recent move by HHS secretary Alex Azar to personally sign off on every rule.